HomeCompareEMBT vs KMB

EMBT vs KMB: Dividend Comparison 2026

EMBT yields 2000000.06% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMBT wins by $4.8792278646347776e+39M in total portfolio value
10 years
EMBT
EMBT
● Live price
2000000.06%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.8792278646347776e+39M
Annual income
$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00
Full EMBT calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — EMBT vs KMB

📍 EMBT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMBTKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMBT + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMBT pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMBT
Annual income on $10K today (after 15% tax)
$170,000,005.10/yr
After 10yr DRIP, annual income (after tax)
$4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, EMBT beats the other by $4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMBT + KMB for your $10,000?

EMBT: 50%KMB: 50%
100% KMB50/50100% EMBT
Portfolio after 10yr
$2.4396139323173888e+39M
Annual income
$2,439,374,001,430,694,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

EMBT
No analyst data
Altman Z
-1935.4
Piotroski
1/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMBT buys
0
KMB buys
0
No recent congressional trades found for EMBT or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMBTKMB
Forward yield2000000.06%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$4.8792278646347776e+39M$45.9K
Annual income after 10y$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00$5,211.33
Total dividends collected$4.8791964691115763e+39M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: EMBT vs KMB ($10,000, DRIP)

YearEMBT PortfolioEMBT Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$200,010,706$200,000,006.00$11,314$613.68+$200.00MEMBT
2$3,738,731,992,770$3,738,517,981,314.42$12,865$759.19+$3738731.98MEMBT
3$65,315,068,744,949,500$65,311,068,301,717,240.00$14,709$943.96+$65315068744.93MEMBT
4$1,066,400,958,023,135,400,000$1,066,331,070,899,578,300,000.00$16,919$1,180.17+$1066400958023135.38MEMBT
5$16,272,185,237,131,282,000,000,000$16,271,044,188,106,197,000,000,000.00$19,588$1,484.33+$16272185237131282432.00MEMBT
6$232,054,281,880,765,440,000,000,000,000$232,036,870,642,561,700,000,000,000,000.00$22,838$1,879.06+$2.3205428188076545e+23MEMBT
7$3,092,799,715,549,616,000,000,000,000,000,000$3,092,551,417,468,003,600,000,000,000,000,000.00$26,832$2,395.60+$3.0927997155496157e+27MEMBT
8$38,524,114,942,504,994,000,000,000,000,000,000,000$38,520,805,646,809,356,000,000,000,000,000,000,000.00$31,788$3,077.63+$3.8524114942504996e+31MEMBT
9$448,468,947,092,778,960,000,000,000,000,000,000,000,000$448,427,726,289,790,500,000,000,000,000,000,000,000,000.00$38,000$3,986.82+$4.4846894709277894e+35MEMBT
10$4,879,227,864,634,777,500,000,000,000,000,000,000,000,000,000$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00$45,872$5,211.33+$4.8792278646347776e+39MEMBT

EMBT vs KMB: Complete Analysis 2026

EMBTStock

Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease. The company also holds approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York.

Full EMBT Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this EMBT vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMBT vs SCHDEMBT vs JEPIEMBT vs OEMBT vs KOEMBT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.